Clinical evidence shows that AposHealth (an FDA-cleared medical device) improves pain, stiffness, and function in people with knee osteoarthritis.
However, it’s uncertain if these improvements are clinically meaningful. The analyses suggest that AposHealth is cost saving by £1,958 per person when compared with standard care if knee surgery is delayed for 5 years. Because the evidence for the potential cost savings is limited, further data collection is recommended to understand if cost savings are made once AposHealth is used in the NHS.
Recent Posts
Global Instability Impacting Generic Pharmaceutical Sustainability in Portugal
Global instability impacting generic pharmaceutical sustainability has become a pressing challenge for Portugal, where rising international conflicts are undermining the economic viability of generic drug production. After 34 years of ensuring affordable access to essential treatments, these medi...
Omaveloxolone Appropriate Utilization Consensus Framework for Friedreich Ataxia
The omaveloxolone appropriate utilization consensus delivers a tightly controlled framework for using Skyclarys in Friedreich’s ataxia, restricting initiation and discontinuation decisions to two specialized Dutch centers. By combining validated functional scales with strict safety thresholds and...
Conditional Adoption Pathways for Endometriosis Diagnostics
The introduction of conditional adoption pathways for endometriosis offers a structured route to faster diagnosis for the millions of women facing four-to-ten-year delays within the NHS. N...